A non-interventional, prospective, multicenter study to describe patient preference and real-world outcomes of Diroximel Fumarate for the treatment of relapsing remitting multiple sclerosis in daily clinical practice
- Conditions
- G35.1
- Registration Number
- DRKS00029567
- Lead Sponsor
- Biogen GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 118
1. Established clinical diagnosis of relapsing-remitting MS
2. Able to understand the purpose and risks of the study, ability and willingness to follow study procedures, and provide signed and dated study-specific informed consent form (ICF)
3. Having been prescribed treatment with Vumerity (DRF) or Tecfidera (DMF) according to label and local market reimbursement criteria and treatment is planned to be initiated within 30 days after enrollment or already initiated, with enrollment occurring no more than 30 days after the first dose.
4. Patients aged 18 years or above
1. Contraindication to dimethyl or diroximel fumarate treatment according to SmPC
2. Unable or unwilling to provide informed consent
3. Progressive forms of MS
4. Have received the newly prescribed treatment with DRF / DMF for more than 30 days
5. Have been prescribed another DMF than Tecfidera
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number and proportion of patients confirming their treatment decision for DRF after one year of treatment / end of study (EOS) as well as their reasoning.
- Secondary Outcome Measures
Name Time Method